Strides Pharma Science Bilan de santé
Santé financière contrôle des critères 3/6
Strides Pharma Science possède un total de capitaux propres de ₹22.1B et une dette totale de ₹22.2B, ce qui porte son ratio d'endettement à 100%. Son actif total et son passif total sont ₹59.9B et de ₹37.7B. L'EBIT de Strides Pharma Science est ₹6.7B ce qui fait que son ratio de couverture des intérêts 2.7. Elle dispose de liquidités et de placements à court terme de ₹2.5B.
Informations clés
100.0%
Ratio d'endettement
₹22.15b
Dette
| Ratio de couverture des intérêts | 2.7x |
| Argent liquide | ₹2.47b |
| Fonds propres | ₹22.15b |
| Total du passif | ₹37.75b |
| Total des actifs | ₹59.90b |
Mises à jour récentes de la santé financière
Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29
We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Recent updates
Strides Pharma Science's (NSE:STAR) Solid Earnings Are Supported By Other Strong Factors
Nov 01Why Investors Shouldn't Be Surprised By Strides Pharma Science Limited's (NSE:STAR) 27% Share Price Surge
Oct 21After Leaping 29% Strides Pharma Science Limited (NSE:STAR) Shares Are Not Flying Under The Radar
Aug 14Investors Still Waiting For A Pull Back In Strides Pharma Science Limited (NSE:STAR)
Apr 04Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Feb 29Strides Pharma Science Limited's (NSE:STAR) Shares Leap 31% Yet They're Still Not Telling The Full Story
Dec 23We Think Strides Pharma Science (NSE:STAR) Is Taking Some Risk With Its Debt
Sep 26Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Jun 08Strides Pharma Science Limited (NSE:STAR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
Aug 02Is Strides Pharma Science (NSE:STAR) A Risky Investment?
Jun 25Does Strides Pharma Science (NSE:STAR) Have A Healthy Balance Sheet?
Dec 21Strides Pharma Science (NSE:STAR) Has Announced That It Will Be Increasing Its Dividend To ₹2.50
Jul 28Estimating The Fair Value Of Strides Pharma Science Limited (NSE:STAR)
Apr 13Should Strides Pharma Science Limited (NSE:STAR) Be Part Of Your Dividend Portfolio?
Mar 04These 4 Measures Indicate That Strides Pharma Science (NSE:STAR) Is Using Debt Extensively
Feb 15Can Mixed Fundamentals Have A Negative Impact on Strides Pharma Science Limited (NSE:STAR) Current Share Price Momentum?
Jan 26The Strides Pharma Science (NSE:STAR) Share Price Is Up 140% And Shareholders Are Boasting About It
Jan 11
Analyse de la situation financière
Passif à court terme: Les actifs à court terme de STAR ( ₹30.9B ) dépassent ses passifs à court terme ( ₹29.6B ).
Passif à long terme: Les actifs à court terme de STAR ( ₹30.9B ) dépassent ses passifs à long terme ( ₹8.1B ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de STAR ( 88.9% ) est considéré comme élevé.
Réduire la dette: Le ratio d'endettement de STAR est passé de 67.5% à 100% au cours des 5 dernières années.
Couverture de la dette: La dette de STAR est bien couverte par le flux de trésorerie opérationnel ( 36.9% ).
Couverture des intérêts: Les paiements d'intérêts de STAR sur sa dette ne sont pas bien couverts par l'EBIT ( 2.7 x couverture).